Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyra TherapeuticsLYRA 29 PS Ratio is 1.77 as of Jul. 23, 2026, which is 96% below its 10-year median of 41.79. GuruFocus rates LYRA with a GF Score™ of 29/100 and a GF Value™ of $2.52 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Lyra Therapeutics ranks better than 86.13% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lyra Therapeutics's share price is $0.52.
Lyra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.29. Hence, Lyra Therapeutics's PS Ratio for today is 1.77.
The historical rank and industry rank for Lyra Therapeutics's PS Ratio or its related term are showing as below:
During the past 8 years, Lyra Therapeutics's highest PS Ratio was 8712.96. The lowest was 1.67. And the median was 41.79.
LYRA's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.22 * Ranked among companies with meaningful PS Ratio only.
During the past 8 years, Lyra Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 2.40% per year. The lowest was -52.10% per year. And the median was -51.60% per year.
Back to Basics: PS Ratio
Lyra Therapeutics (OTCPK:LYRA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lyra Therapeutics PS Ratio Related Terms
Lyra Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Lyra Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lyra Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lyra Therapeutics's Share Price of today is $0.52. Lyra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.29.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lyra Therapeutics (LYRA) has a PS Ratio of 1.77 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lyra Therapeutics and its competitors. This is 96% below median its historical median of 41.79. Over the past decade, Lyra Therapeutics' PS Ratio has ranged from 1.67 to 8,712.96. According to the industry distribution chart, Lyra Therapeutics ranks #129 out of 930 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Lyra Therapeutics' PS Ratio too high?
Lyra Therapeutics' current PS Ratio of 1.77 is 96% below median its 10-year median of 41.79. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 8,712.96. The Biotechnology industry median PS Ratio is 9.22. Lyra Therapeutics' value of 1.77 is 80.8% below this industry median. Based on the distribution chart, Lyra Therapeutics ranks #129 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lyra Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' PS Ratio compare to EVFM and CLSDQ?
According to the Biotechnology industry distribution chart, Lyra Therapeutics ranks #129 out of 930 companies for PS Ratio. This places Lyra Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.22. Lyra Therapeutics' value of 1.77 is 80.8% below this benchmark. Historically, Lyra Therapeutics' own PS Ratio has ranged from 1.67 to 8,712.96 over the past decade. While the company's 10-year median is 41.79 vs. the industry median of 9.22, Lyra Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.22, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyra Therapeutics's current PS Ratio of 1.77 is 80.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lyra Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyra Therapeutics's current PS Ratio is 1.77, which is 96% below median its own 10-year median of 41.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.52, compared to a current price of $0.52 — trading 79.4% below its estimated fair value. The current PS Ratio is 1.77, which is 96% below median its 10-year median of 41.79 and 80.8% below the Biotechnology industry median of 9.22. Lyra Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current PS Ratio is 1.77 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyra Therapeutics (LYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued.
The current stock price of $0.52 is trading 79.4% below its estimated GF Value™ of $2.52.
GuruFocus considers Lyra Therapeutics to be Possible Value Trap.
Key valuation signals for LYRA:
PS Ratio: 1.77 (96% below median its 10-year median of 41.79)
GF Value™: $2.52 vs. price of $0.52 (79.4% below fair value)
Industry Position: 80.8% below the Biotechnology median (#129 of 930)
No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
29GF Score
Get the complete analysis for LYRA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYRA has been successfully added to your 
